Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...
Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...
The FDA’s approval for Celcuity’s cancer drug Revtorpyk on Tuesday was widely anticipated. What Wall Street didn’t expect was that the ...
Researchers had been testing whether Artiva's off-the-shelf NK cell therapy called AB-101 could treat rheumatoid arthritis and other autoimmune diseases.
Q3 Biopharma Sentiment Index shows regulatory optimism rising after Marty Makary and Vinay Prasad's FDA exits, though scientists remain pessimistic.
Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
Microsoft’s MAI-DxO diagnosed 83% of complex journal cases vs. 36% for doctors; a Beth Israel triage study starts within ...
BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...
Aspen, Bambusa eye $135M IPOs; ESMO data on AZ/Takeda ADCs, Hutchmed's Orpathys+Tagrisso, J&J's JNJ-6143, Jazz's Ziihera; ...
WuXi AppTec raises 2026 guidance again as Q3 revenue jumps 38% to $2.5B, despite its fight over the Pentagon’s Chinese military designation ...
Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results